Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

In Boston’s Class A office towers, brokerage CBRE says worker ... mostly to keep the same space or add more: Vertex, Ropes & Gray, Bain Capital, and Converse. That’s encouraging.

More than 60 WBUR listeners and readers shared their stories — and photos — with us to collectively commemorate, rage and ...

Heartland Business Systems, CDW, Leidos, SAP, SAS and Vertex are among the companies ... Accounts in the East New England Area (NY, Philly, Boston)” and boost information protection sales.

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...